HUP0400654A2 - 4-Foszfo-diészteráz-inhibitorként ható 8-aril-kinolin-származékok és ezeket tartalmazó gyógyszerkészítmények - Google Patents

4-Foszfo-diészteráz-inhibitorként ható 8-aril-kinolin-származékok és ezeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0400654A2
HUP0400654A2 HU0400654A HUP0400654A HUP0400654A2 HU P0400654 A2 HUP0400654 A2 HU P0400654A2 HU 0400654 A HU0400654 A HU 0400654A HU P0400654 A HUP0400654 A HU P0400654A HU P0400654 A2 HUP0400654 A2 HU P0400654A2
Authority
HU
Hungary
Prior art keywords
group
alkyl
substituted
aryl
son
Prior art date
Application number
HU0400654A
Other languages
English (en)
Inventor
Sophie-Dorothee Clas
David A. Conlon
Guo-Jie Ho
Elizabeth Kwong
Dwight Mcdonald
Helene Perrier
Roch Thibert
Anant Vailaya
Original Assignee
Merck & Co., Inc.
Merck Frosst Canada & Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co., Inc., Merck Frosst Canada & Co. filed Critical Merck & Co., Inc.
Publication of HUP0400654A2 publication Critical patent/HUP0400654A2/hu
Publication of HUP0400654A3 publication Critical patent/HUP0400654A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A találmány 8-aril-kinolin-származékokra, különösen a 8-as helyzetbenhelyettesített alkenilcsoporttal szubsztituált arilcsoportottartalmazó 8-aril-kinolin-származékok sóira vonatkozik, amelyekgátolják a 4-foszfo-diészteráz enzim működését. A találmány szerinti8-aril-kinolin-származékok (I) általános képletében S1, S2 és S3jelentése egyaránt hidrogénatom; R1 jelentése hidrogénatom,hidroxilcsoport, halogénatom, karbonilcsoport, alkilcsoport,cikloalkilcsoport, alkenilcsoport, alkoxicsoport, arilcsoport,heteroarilcsoport, cianocsoport, heterocikloalkilcsoport,aminocsoport, alkil-amino-csoport, dialkil-amino-csoport, alkiloxi-alkil-csoport, (aril)-aminokarbonil-csoport, (heteroaril)-aminokarbonil-csoport, aril-amino-SOn-csoport, heteroaril-aminoSOn-csoport, alkil-amino-SOn-csoport, dialkil-amino-karbonil-csoport,alkilSOn-amino-csoport, alkil-SOn-csoport, di(alkil-amino)-C(CN)-O(alkil)-csoport vagy (alkil)-SOn(alkil)-csoport, azzal amegjegyzéssel, hogy a csoportok 1-5 egymástól függetlenszubsztituenssel adott esetben helyettesítve lehetnek; A jelentése CHképletű csoport; R2 és R3 jelentése - egymástól függetlenül -arilcsoport, heteroarilcsoport, hidrogénatom, halogénatom,cianocsoport, alkilcsoport, heterocikloalkilcsoport, alkoxicsoport,karbonilcsoport, karbamoilcsoport, (alkil)-SOn-(alkil)-csoport,dialkilamino-karbamoil-csoport vagy amino-alkil-acil-csoport, azzal amegjegyzéssel, hogy a csoportok adott esetben helyettesítve lehetnek1-5 olyan szubsztituenssel, amelyek maguk is lehetnek szubsztituáltak;R4 jelentése arilcsoport, alkilcsoport, heteroarilcsoport,cianocsoport, karbonilcsoport, karbamoilcsoport, (alkil)-SOn-(alkil)-csoport, dialkil-amino-karbonilcsoport vagy amino-acil-alkil-csoport,azzal a megjegyzéssel, hogy a csoportok 1-5 szubsztituenssel adottesetben helyettesítve lehetnek; és n jelentése 0, 1 vagy 2. Atalálmány kiterjed a vegyületeket tartalmazó gyógyszerkészítményekreis. Ó
HU0400654A 2000-12-20 2001-12-14 Substituted 8-arylquinoline phosphodiesterase 4 inhibitors and pharmaceutical compositions containing them HUP0400654A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25680300P 2000-12-20 2000-12-20
PCT/US2001/048674 WO2002069970A1 (en) 2000-12-20 2001-12-14 Substituted 8-arylquinoline phosphodiesterase-4 inhibitors

Publications (2)

Publication Number Publication Date
HUP0400654A2 true HUP0400654A2 (hu) 2004-06-28
HUP0400654A3 HUP0400654A3 (en) 2011-07-28

Family

ID=22973639

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0400654A HUP0400654A3 (en) 2000-12-20 2001-12-14 Substituted 8-arylquinoline phosphodiesterase 4 inhibitors and pharmaceutical compositions containing them

Country Status (28)

Country Link
US (1) US6740666B2 (hu)
EP (1) EP1363635B1 (hu)
JP (1) JP2004521921A (hu)
KR (1) KR20030063456A (hu)
CN (1) CN100508978C (hu)
AR (1) AR035514A1 (hu)
AT (1) ATE428420T1 (hu)
AU (1) AU2001297603B2 (hu)
BG (1) BG107900A (hu)
BR (1) BR0116372A (hu)
CA (1) CA2431549A1 (hu)
CZ (1) CZ20031738A3 (hu)
DE (1) DE60138421D1 (hu)
DO (1) DOP2001000308A (hu)
EA (1) EA006607B1 (hu)
EE (1) EE200300266A (hu)
HU (1) HUP0400654A3 (hu)
IL (1) IL156479A0 (hu)
JO (1) JO2317B1 (hu)
MX (1) MXPA03005673A (hu)
MY (1) MY136792A (hu)
NO (1) NO20032807L (hu)
NZ (1) NZ526376A (hu)
PE (1) PE20020787A1 (hu)
PL (1) PL362564A1 (hu)
SK (1) SK7732003A3 (hu)
WO (1) WO2002069970A1 (hu)
ZA (1) ZA200304672B (hu)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4141838B2 (ja) * 2000-12-20 2008-08-27 メルク エンド カムパニー インコーポレーテッド 置換８−アリールキノリニウムベンゼンスルホネートを生成するための方法
AU2003209896A1 (en) * 2002-03-18 2003-09-29 Merck Frosst Canada And Co. Hetero-bridge substituted 8-arylquinoline pde4 inhibitors
CA2515407A1 (en) * 2003-02-10 2004-08-26 Todd Ovokaitys Enhanced bioavailability of nutrients, pharmaceutical agents, and other bioactive substances through laser resonant homogenization or modification of molecular shape or crystalline form
GB0307863D0 (en) * 2003-04-04 2003-05-14 Merck Sharp & Dohme Therapeutic treatment
WO2005009342A2 (en) * 2003-07-16 2005-02-03 Pharmacia Corporation Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
CN100425591C (zh) * 2005-09-26 2008-10-15 山东大学 含有磺酰基二苯基乙烯桥化合物及其制法和药物应用
US20100048713A1 (en) * 2006-01-06 2010-02-25 Aarhus Universitet Compounds acting on the serotonin transporter
SI2363130T1 (sl) 2006-07-05 2014-09-30 Takeda Gmbh Kombinacija inhibitorjev HMG-CoA reduktaze atorvastatina ali simvastatina z inhibitorjem fosfodiesteraze 4, kot je roflumilast, za zdravljenje vnetnih pljučnih bolezni
US8258154B2 (en) * 2006-07-07 2012-09-04 Kalypsys Inc. Bicyclic heteroaryl inhibitors of PDE4
US20090182035A1 (en) * 2007-04-11 2009-07-16 Alcon Research, Ltd. Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
MX2009010946A (es) * 2007-04-11 2009-10-29 Alcon Res Ltd Uso de un inhibidor del factor de necrosis tumoral alfa mas una antihistamina para tratar rinitis alergica y conjuntivitis alergica.
EP2674417A3 (en) * 2007-11-21 2014-04-09 Decode Genetics EHF Biaryl PDE4 inhibitors for treating inflammation
EP2482798A1 (en) * 2009-10-01 2012-08-08 Alcon Research, Ltd. Olopatadine compositions and uses thereof
US8367829B2 (en) 2010-05-10 2013-02-05 Gilead Sciences, Inc. Bi-functional pyrazolopyridine compounds
EP2569285A1 (en) 2010-05-10 2013-03-20 Gilead Sciences, Inc. Bifunctional quinoline derivatives
SG11202106517WA (en) 2018-12-28 2021-07-29 Regeneron Pharma Treatment of respiratory disorders with arachidonate15-lipoxygenase (alox15) inhibitors
US20240199661A1 (en) * 2021-03-31 2024-06-20 Riboscience Llc Bicyclic heteroaryl phosphonate derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9212673D0 (en) 1992-06-15 1992-07-29 Celltech Ltd Chemical compounds
GB9212693D0 (en) 1992-06-15 1992-07-29 Celltech Ltd Chemical compounds
DE59304166D1 (de) 1992-07-01 1996-11-21 Hoechst Ag 3,4,5-Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
GB9222253D0 (en) 1992-10-23 1992-12-09 Celltech Ltd Chemical compounds
GB9226830D0 (en) 1992-12-23 1993-02-17 Celltech Ltd Chemical compounds
US5622977A (en) 1992-12-23 1997-04-22 Celltech Therapeutics Limited Tri-substituted (aryl or heteroaryl) derivatives and pharmaceutical compositions containing the same
DE4306152A1 (de) 1993-02-27 1994-09-01 Hoechst Ag Positiv arbeitendes strahlungsempfindliches Gemisch und damit hergestelltes Aufzeichnungsmaterial
GB9304920D0 (en) 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9304919D0 (en) 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
US5455252A (en) 1993-03-31 1995-10-03 Syntex (U.S.A.) Inc. Optionally substituted 6,8-quinolines
DE4318756A1 (de) 1993-06-05 1994-12-08 Hoechst Ag Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
GB9326600D0 (en) 1993-12-22 1994-03-02 Celltech Ltd Chemical compounds
GB9326173D0 (en) 1993-12-22 1994-02-23 Celltech Ltd Chemical compounds and process
DE69433594T2 (de) 1993-12-22 2004-08-05 Celltech R&D Ltd., Slough Trisubstituierte phenyl-derivate, verfahren zu deren herstellung und deren verwendung als phosphodiesterase (typ iv) hemmstoffe
US6245774B1 (en) 1994-06-21 2001-06-12 Celltech Therapeutics Limited Tri-substituted phenyl or pyridine derivatives
US5786354A (en) 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
GB9412573D0 (en) 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412571D0 (en) 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412672D0 (en) 1994-06-23 1994-08-10 Celltech Ltd Chemical compounds
EP0765867A1 (de) 1995-09-27 1997-04-02 Hoechst Aktiengesellschaft Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Antiarrhytmika oder Diagnostikum sowie sie enthaltendes Medikament
GB9526246D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526245D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526243D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
DE19622370A1 (de) 1996-06-04 1997-12-11 Hoechst Ag Ortho-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
GB9625184D0 (en) 1996-12-04 1997-01-22 Celltech Therapeutics Ltd Chemical compounds
JP4099237B2 (ja) 1996-12-11 2008-06-11 アボット ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト カルパインインヒビターとしてのケトベンズアミド
JPH11209350A (ja) 1998-01-26 1999-08-03 Eisai Co Ltd 含窒素複素環誘導体およびその医薬
MY134008A (en) * 1999-12-22 2007-11-30 Merck Frosst Canada Inc Subtituted 8-arylquinoline phospohodiestrase-4 inhibitors
US6410563B1 (en) * 1999-12-22 2002-06-25 Merck Frosst Canada & Co. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
JP4415360B2 (ja) 2000-01-28 2010-02-17 エプソントヨコム株式会社 縦結合弾性表面波フィルタ

Also Published As

Publication number Publication date
IL156479A0 (en) 2004-01-04
US6740666B2 (en) 2004-05-25
EE200300266A (et) 2003-10-15
NO20032807D0 (no) 2003-06-19
CN100508978C (zh) 2009-07-08
PL362564A1 (en) 2004-11-02
NZ526376A (en) 2005-02-25
BG107900A (bg) 2004-06-30
EP1363635B1 (en) 2009-04-15
HUP0400654A3 (en) 2011-07-28
AU2001297603B2 (en) 2006-02-16
NO20032807L (no) 2003-08-15
MXPA03005673A (es) 2003-10-06
PE20020787A1 (es) 2002-09-10
ZA200304672B (en) 2004-04-21
JP2004521921A (ja) 2004-07-22
ATE428420T1 (de) 2009-05-15
DOP2001000308A (es) 2002-07-15
CA2431549A1 (en) 2002-09-12
SK7732003A3 (en) 2003-11-04
US20020143032A1 (en) 2002-10-03
KR20030063456A (ko) 2003-07-28
WO2002069970A1 (en) 2002-09-12
EP1363635A1 (en) 2003-11-26
AR035514A1 (es) 2004-06-02
CZ20031738A3 (cs) 2003-11-12
JO2317B1 (en) 2005-09-12
EA006607B1 (ru) 2006-02-24
EA200300706A1 (ru) 2003-12-25
DE60138421D1 (en) 2009-05-28
BR0116372A (pt) 2003-12-09
MY136792A (en) 2008-11-28
CN1551769A (zh) 2004-12-01

Similar Documents

Publication Publication Date Title
HUP0400654A2 (hu) 4-Foszfo-diészteráz-inhibitorként ható 8-aril-kinolin-származékok és ezeket tartalmazó gyógyszerkészítmények
HUP0002353A2 (hu) IV típusú foszfodiészteráz inhibitor hatású 1-cikloalkil-1,8-naftiridin-4-on-származékok és ezeket a vegyületeket tartalmazó gyógyszerkészítmények
HUP0300350A2 (hu) Új 3-amino-azetidin-származékok, előállításuk és ezeket tartalmazó gyógyszerkészítmények
HUP0001054A2 (hu) IV-típusú foszfodiészteráz inhibitor 1-aril-1,8-naftiridin-4-on-származékok
HUP0300527A2 (hu) Pirrolopirimidinon-származékok, a vegyületek előállítása és alkalmazása
HUP0302435A2 (hu) 11-Béta-hidroxiszteroid dehidrogenáz 1 típusú enzimet gátló anyagok és ezeket tartalmazó gyógyszerkészítmények
ATE479667T1 (de) Als kinaseinhibitoren geeignete verbindungen auf thiazolylbasis
CA2432713A1 (en) Aniline derivatives or salts thereof and cytokine production inhibitors containing the same
DK1070056T3 (da) Phthalazinon-PDE III/IV-inhibitorer
ATE321038T1 (de) Chinolin- und chinazolinderivate und deren verwendung als farnesyl transferase inhibitoren
TW200510338A (en) 3-substituted-4-pyrimidone derivatives
HUP0301514A2 (hu) Benzimidazol származékok, elżállításuk és ezeket tartalmazó gyógyszerkészítmények
HUP0302792A2 (hu) Dipeptidil peptidáz ciklopropil-kondenzált pirrolidin-bázisú inhibitorai és eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények
HUP0300565A2 (hu) PDE 5 inhibitor hatású 8-kinolin-xantin- és 8-izo-kinolin-xantin-származékok, alkalmazásuk, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0204474A2 (hu) 1H-imidazopiridin-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0300329A2 (hu) Malonaminsavak és származékai és alkalmazásuk pajzsmirigy receptor ligandumként és ezeket tartalmazó gyógyszerkészítmények előállítására
MEP25608A (en) Derivatives of n-[phenyl(piperidin-2-yl)methyl]benzamide, the preparation method thereof and application of same in therapeutics
DE69903976D1 (de) Heteroaryl-zyklische acetale
HUP0402171A2 (hu) PDE7 inhibitor hatással rendelkező pirazolopirimidinon-származékok
HRP20070132T3 (en) Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
HRP20020264B1 (en) 2'-substituted 1,1'-biphenyl-2-carbonamides, method for the production thereof, use thereof as a medicament and pharmaceutical preparations containing said compounds
NO20022125L (no) Pyrrolderivater som inhibitorer for fosfodiesterase VII
NO982901L (no) Nye barbitursyrederivater, fremgangsmåter for fremstilling av slike, samt farmasöytiske midler inneholdende disse forbindelser
HUP0402244A2 (hu) Heterociklusos glicinamid-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0301587A2 (hu) Foszfodiészteráz V gátló hatású 5-amino-alkil-pirazolo[4,3-d]pirimidinek, ezeket tartalmazó gyógyszerkészítmények és eljárások az elżállításaikra

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: MERCK FROSST CANADA LTD., CA

Free format text: FORMER OWNER(S): MERCK & CO., INC., US; MERCK FROSST CANADA & CO., CA

Owner name: MERCK & CO., INC., US

Free format text: FORMER OWNER(S): MERCK & CO., INC., US; MERCK FROSST CANADA & CO., CA

FD9A Lapse of provisional protection due to non-payment of fees